Progesterone intravenous - BHR Pharma

Drug Profile

Progesterone intravenous - BHR Pharma

Alternative Names: BHR-100

Latest Information Update: 14 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BHR Pharma
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Apoptosis inhibitors; GABA modulators; Glutamate-antagonists; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Lipid peroxidation inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain injuries
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Brain injuries

Most Recent Events

  • 01 Mar 2014 BHR Pharma complete the global phase III SyNAPSe trial for Brain injuries in USA, Argentina, China, Europe, Israel, Malaysia, Russia, Singapore, Taiwan and Thailand (NCT01143064)
  • 03 Sep 2013 BHR Pharma completes enrolment in the global phase III SyNAPSe trial for Brain injuries (NCT01143064)
  • 22 Jul 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top